8-K: Phathom Pharmaceuticals' VOQUEZNA Gains National Formulary Access with Express Scripts

Phathom Pharmaceuticals announced that Express Scripts, a major U.S. pharmacy benefit manager, has added VOQUEZNA to its national formularies for commercial plans, effective immediately.

Summary

• Phathom Pharmaceuticals has secured a significant formulary placement for its drug VOQUEZNA.
• Express Scripts, a leading U.S. pharmacy benefit manager, will now include VOQUEZNA on its national formularies for commercial plans.
• This change is effective immediately as of February 13, 2024.
• The formulary placement allows patients to access VOQUEZNA with a single step through a generic proton pump inhibitor (PPI).

Sentiment

Score: 9

Explanation: The announcement of a major formulary placement is a very positive development for the company, indicating strong market access and potential for increased sales.

Positives

• The inclusion of VOQUEZNA on Express Scripts' national formularies significantly expands patient access to the drug.
• The single-step access through a generic PPI simplifies the process for patients to obtain VOQUEZNA.
• This formulary placement is effective immediately, allowing for rapid uptake of the drug.

Risks

• The document does not mention any risks.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

This announcement is significant as it indicates growing acceptance and market access for Phathom Pharmaceuticals' VOQUEZNA, which is crucial for its commercial success in the competitive pharmaceutical landscape.

Comparison to Industry Standards

• Formulary placement with major pharmacy benefit managers like Express Scripts is a key indicator of a drug's market potential and acceptance.
• Gaining access to national formularies is a common goal for pharmaceutical companies launching new drugs, and this achievement positions Phathom Pharmaceuticals favorably compared to competitors who may not have secured similar access.
• The single-step access through a generic PPI is a positive differentiator, as it simplifies the process for patients compared to drugs with more complex access requirements.

Stakeholder Impact

• Shareholders will likely view this announcement positively due to the increased market access for VOQUEZNA.
• Patients will benefit from easier access to VOQUEZNA through their commercial insurance plans.
• The company's employees may see this as a positive step towards the company's growth and success.

Key Dates

Keywords

VOQUEZNA, Phathom Pharmaceuticals, Express Scripts, formulary, pharmacy benefit manager, PPI, proton pump inhibitor